Prevention of disease Archives - Page 4 of 6

From 2023 onwards we modelled a combination of interventions acting at different stages of the care cascade, including improved diagnostics; reducing the patient care seeking delay; and the rollout of a disease-preventing vaccine from 2025 onwards.

Impact and cost-effectiveness of new tuberculosis vaccines in low- and middle-income countries.

2014

Hypothetical vaccines, M72/AS01e

To aid in prioritizing the development of tuberculosis (TB) vaccines most likely to reach the 2050 TB elimination goal, we estimated the impact and cost-effectiveness of a range of vaccine profiles in low- and middle-income countries.

TbVacMod; Estimating the epidemiologic impact of new TB vaccines in high-burden settings

2022-2027

This is an NIH-funded study which will estimate the health impact of introducing a prevention of disease vaccine for adult and adolescents in moderate to high TB burden countries. We are developing model scenarios based on input from country stakeholders, including national TB program and immunization program officials.

Estimating the epidemiologic impact of new TB vaccines in the U.S.

2022-2024

This is a study funded by the American Lung Association which will explore the potential impact of targeted implementation of a prevention of disease vaccine in a low TB burden country, the U.S.A.

Formative work to understand factors affecting future TB vaccines acceptance and readiness

2023-2027

This project aims to collect data to: 1) Assess health facility and health systems readiness for a new TB vaccine, and 2) Explore decision-making factors for new TB vaccine demand and acceptance

Is neglect of self-clearance biasing TB vaccine impact estimates?

exploring the inclusion of self-clearance in models of tuberculosis affects the estimates of vaccine impact in China and India

Demand insights for uptake of TB vaccine

2022

Summarize the major swing factors that would determine countries’ preference and effectively drive the uptake of a TB vaccine in terms of the date of introduction and the scale of catch-up campaign to reach the steady state

The cost and cost-effectiveness of novel tuberculosis vaccines in low- and middle-income countries: A modeling study

We assessed future costs, cost-savings, and cost-effectiveness of introducing novel TB vaccines in low- and middle-income countries (LMICs) for a range of product characteristics and delivery strategies.

The potential impact of novel tuberculosis vaccines on health equity and financial protection in low-income and middle-income countries

We assessed the potential financial risk protection from introducing novel TB vaccines, and how health and economic benefits would be distributed across income quintiles.

Acceptability and effect on public and cost-effectiveness impact

BCG revaccination, M72/AS01e